butaclamol has been researched along with Pituitary Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cronin, MJ; Faure, N; Martial, JA; Weiner, RI | 1 |
| Senogles, SE | 1 |
| Benedetto, P; Feigenblum, D; Filer, D; Goldstein, M; Lew, JY; Tang, D; Zawadzka, H | 1 |
3 other study(ies) available for butaclamol and Pituitary Neoplasms
| Article | Year |
|---|---|
Decreased responsiveness of GH3 cells to the dopaminergic inhibition of prolactin.
Topics: Animals; Apomorphine; Bromocriptine; Butaclamol; Cell Line; Clone Cells; Dopamine; Dose-Response Relationship, Drug; Mice; Pituitary Neoplasms; Prolactin | 1980 |
The D2 dopamine receptor mediates inhibition of growth in GH4ZR7 cells: involvement of protein kinase-C epsilon.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Alprenolol; Animals; Apomorphine; Benzazepines; Butaclamol; Carcinogens; Cell Division; Cell Line; DNA; Dopamine; Ergolines; Humans; Isoenzymes; Kinetics; Norepinephrine; Pertussis Toxin; Phorbol Esters; Pituitary Neoplasms; Protein Kinase C; Quinpirole; Receptors, Dopamine D2; Salicylamides; Spiperone; Thymidine; Transfection; Tumor Cells, Cultured; Virulence Factors, Bordetella | 1994 |
Regulation and molecular characterization of dopamine D2 receptors in a prolactin-secreting 7315a anterior pituitary tumor.
Topics: Animals; Azides; Blotting, Northern; Butaclamol; Corpus Striatum; Female; Haloperidol; In Vitro Techniques; Kinetics; Neoplasms, Experimental; Pituitary Gland, Anterior; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred BUF; Receptors, Dopamine; RNA, Messenger; Spiperone | 1990 |